Cited by 486Trauma, Hemostasis, Coagulopathy, ResuscitationSepsis Diagnosis and TreatmentHemodynamic Monitoring and Therapy

The DOI matches its Crossref record; 110 of the 112 references it cites were found in a registry or an index.

Patient Survival after Human Albumin Administration: A Meta-Analysis of Randomized, Controlled Trials

Wilkes, Mahlon M., Navickis, Roberta J.·2001·Annals of Internal Medicine

Abstract

PURPOSE: To test the hypothesis that albumin administration is not associated with excess mortality. DATA SOURCES: Computer searches of the MEDLINE and EMBASE databases, the Cochrane Library, and Internet documents; hand searching of medical journals; inquiries to investigators and medical directors; and review of reference lists. STUDY SELECTION: Randomized, controlled trials comparing albumin therapy with crystalloid therapy, no albumin, or lower doses of albumin. DATA EXTRACTION: Two investigators independently extracted data. The primary end point was relative risk for death. Criteria used to assess methodologic quality were blinding, method of allocation concealment, presence of mortality as a study end point, and crossover. Small-trial bias was also investigated. DATA SYNTHESIS: Fifty-five trials involving surgery or trauma, burns, hypoalbuminemia, high-risk neonates, ascites, and other indications were included. Albumin administration did not significantly affect mortality in any category of indications. For all trials, the relative risk for death was 1.11 (95% CI, 0.95 to 1.28). Relative risk was lower among trials with blinding (0.73 [CI, 0.48 to 1.12]; n = 7), mortality as an end point (1.00 [CI, 0.84 to 1.18]; n = 17), no crossover (1.04 [CI, 0.89 to 1.22]; n = 35), and 100 or more patients (0.94 [CI, 0.77 to 1.14]; n = 10). In trials with two or more such attributes, relative risk was further reduced. CONCLUSIONS: Overall, no effect of albumin on mortality was detected; any such effect may therefore be small. This finding supports the safety of albumin. The influence of methodologic quality on relative risk for death suggests the need for further well-designed clinical trials.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-135-3-200108070-00007

Cites

110 of 110 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

3 retracted

Show all 112 references

Research works printed but not linked: 23

  1. Rennie M, 1998, Br J Intens Care, 8, 185
  2. Bell E, 1999, Adverse Drug React Toxicol Rev, 18, 149
  3. Cook D, 1999, Evidence-Based Medicine, 1, 19
  4. Mantel N, 1959, J Natl Cancer Inst, 22, 719
  5. Recinos PR, 1975, J Iowa Med Soc, 65, 426
  6. Skillman JJ, 1975, Surgery, 78, 291
  7. Lowe RJ, 1977, Surgery, 81, 676
  8. Virgilio RW, 1979, Surg Forum, 30, 166
  9. Virgilio RW, 1979, Surgery, 85, 129
  10. Nilsson E, 1980, Acta Chir Scand, 146, 619
  11. Metildi LA, 1984, Surg Gynecol Obstet, 158, 207
  12. Nielsen OM, 1985, Acta Chir Scand, 151, 221
  13. Boldt J, 1986, Infusionsther Klin Ernahr, 13, 145
  14. Jones MM, 1986, Obstet Gynecol, 68, 659
  15. Reid DJ, 1988, Clin Pharm, 7, 894
  16. Nielsen OM, 1989, Dan Med Bull, 36, 496
  17. Adam R, 1991, Transplant Proc, 23, 2374
  18. 10.1213/00000539-199376060-00002 · DOI
  19. Woods MS, 1993, Am Surg, 59, 758
  20. Luca A, 1995, Hepatology, 22, 753
  21. Saxena N, 1997, J Anaesth Clin Pharmacol, 13, 117
  22. Hondebrink Y, 1997, Intensive Care Med, 23, S138
  23. Woittiez AJ, 1998, Ned Tijdschr Geneeskd, 142, 2161

Cited by

Sorted by citations

Metadata

Authors
Wilkes, M. M., & Navickis, R. J.
Affiliations
From Hygeia Associates, Grass Valley, California.
Venue
Annals of Internal Medicine
Published
2001-08-07
Volume
135
Issue
3
Pages
149-164
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2129198157
Cited by
486
References
112
Citations by year
2026: 5 · 2025: 4 · 2024: 5 · 2023: 10 · 2022: 2 · 2021: 5 · 2020: 6 · 2019: 11 · 2018: 9 · 2017: 11 · 2016: 18 · 2015: 12 · 2014: 17 · 2013: 14 · 2012: 24
FWCI
6.71
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Trauma, Hemostasis, Coagulopathy, Resuscitation
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
  • Health Sciences › Medicine › Surgery › Hemodynamic Monitoring and Therapy
Keywords
human serum albumin, albumin therapy, mortality, patient survival, hypoalbuminemia, ascites, burns, trauma (physical injury), neonates, methodological quality, trial bias, drug safety
MeSH terms
Albumins, Colloids, Critical Care, Fluid Therapy, Research Design, Risk Factors, Rehydration Solutions, Bias, Survival Analysis, Randomized Controlled Trials as Topic, Critical Illness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review